Under the leadership of Prof John Crown, the Molecular Therapeutics for Cancer research programme aims to investigate response and resistance to cancer treatments and to develop improved treatment strategies for cancer patients.
The research programme is focussed on three key areas:
Caiazza F, McGowan PM, Mullooly M, Murray A, Synnott N, O'Donovan N, Flanagan L, Tape CJ, Murphy G, Crown J, Duffy MJ (2015)Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells. Br J Cancer. 2015 Jun 9;112(12):1895-903. doi: 10.1038/bjc.2015.163. Epub 2015 May 26.
Gaule PB, Crown J, O'Donovan N, Duffy MJ. (2014) cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients? Expert Opin Ther Targets. 2014 Sep;18(9):999-1009. doi: 10.1517/14728222.2014.938050. Epub 2014 Aug 1.
- McDermott MS, Browne BC, Conlon NT, O'Brien NA, Slamon DJ, Henry M, Meleady P, Clynes M, Dowling P, Crown J, O'Donovan N. (2014) PP2A inhibition overcomes acquired resistance to HER2 targeted therapy. Mol Cancer. 2014 Jun 24;13:157. doi: 10.1186/1476-4598-13-157.
Rani S, Corcoran C, Shiels L, Germano S, Breslin S, Madden S, McDermott MS, Browne BC, O'Donovan N, Crown J, Gogarty M, Byrne AT,O'Driscoll L. (2014)Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors. Cancer Res. 2014 Jul 15;74(14):3821-33. doi: 10.1158/0008-5472.CAN-13-2053. Epub 2014 May 29.
- McDermott M, Eustace AJ, Busschots S, Breen L, Crown J, Clynes M, O'Donovan N, Stordal B. (2014) In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies. Front Oncol. 2014 Mar 6;4:40. doi: 10.3389/fonc.2014.00040. eCollection 2014.
- Collins DM, O'Donovan N, McGowan PM, O'Sullivan F, Duffy MJ, Crown J. (2012) Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann Oncol 2012 Jul;23(7):1788-95.
Eustace AJ, Dowling P, Henry M, Doolan P, Meleady P, Clynes M, Crown J, O'Donovan N. (2011) 2D-DIGE analysis of phospho-enriched fractions from dasatinib-treated melanoma cell lines. J Proteomics. 2011 Apr 1;74(4):490-501. doi: 10.1016/j.jprot.2010.12.011. Epub 2011 Jan 13.
Maurya P, Meleady P, Dowling P, Clynes M. (2007) Proteomic approaches for serum biomarker discovery in cancer. Anticancer Res. 2007 May-Jun;27(3A):1247-55.